ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

YONKERS, N.Y., Aug. 15, 2022 -- ContraFect Corporation , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents , including lysins and amurin... | August 15, 2022

Related Keywords

,Cara Cassino ,Garrett Nichols ,Michael Messinger ,Rogerj Pomerantz ,European Congress ,Contrafect Corporation ,Exchange Commission ,Contrafect Corporation Nasdaq ,University Of Washington ,Company Quarterly Report On Form ,Duke University ,Development Of The Company ,Globenewswire Inc ,Fect Corporation ,Chief Executive Officer ,Data Safety Monitoring Board ,Direct Lysis ,Resistant Pathogen Trial ,Chief Medical Officer ,Executive Vice President ,Interim Chief Medical ,Clinical Microbiology ,Infectious Diseases ,Annual Meeting ,Escherichia Coli ,Breakthrough Therapy ,Quarterly Report ,Accepted Accounting Principles ,Annual Report ,Relations Contacts ,Contrafect Corporation Stock Exchange ,News ,Information ,Press Release ,022 ,Contrafect ,Corporation ,Biotechnology ,Company ,Ocused ,N ,The ,Discovery ,End ,Development ,F ,Direct ,Lytic ,Agents ,Ncluding ,Eysins ,Nd Cfrx Us2123263004 ,